transplants. [6] Therefore, an algorithm comprising a combination of tests is used to determine UAM. UAM decides on the patient's chance to receive an organ; a restrictive defined UAM algorithm diminishes the chances of patient receiving an organ dramatically. Conversely, liberal defined UAM algorithm frequently leads to inferior graft survival. [7] There is a need for developing an appropriate algorithm for our resource constraint setting in India. This study [8] is one such welcome step in the direction of using an algorithm of cell-based CDCXM and SPI (Luminex XM [LXM]) test. However, since most of the transplant physicians did transplants in patients with CDC-negative-LXM-positive patients, the rate of AMR appears high. It would be a good idea to restrict transplants in CDC-negative-LXM-positive cases and thereby achieve lower rate of AMR. Authors are encouraged to adopt this algorithm with this new definition of UAM and prove this hypothesis. There is also need for many more reports on various algorithms being practiced and finally a consensus for the country to adopt.
Commentary introDuCtion
Kidney transplantation is the preferred treatment in patients with end-stage renal disease. [1] A systematic review analyzing 110 studies on renal transplantation had most studies finding significantly lower mortality associated with transplantation, and the relative magnitude of the benefit seemed to increase over time. [2] Human leukocyte antigens (HLAs) play an important role in graft survival.
prEtransplant Compatibility tEsts
Detection of HLA antibodies, particularly donor-specific antibodies (DSAs), is a crucial step in pretransplant assessment [3] for optimal donor selection and graft survival. The cell-based assay such as complement-dependent cytotoxicity crossmatch (CDCXM) was introduced in the 1960s. [4] Over the years, other more sensitive methodologies based on flow cytometry and solid-phase immunoassays (SPI) have evolved. While positive CDCXM is considered a contraindication for transplantation, DSA detected by other assays represents varying degrees of risk. It is presently unclear which of the common test [ Table 1 ] is most appropriate for the determination of unacceptable HLA antigen mismatch (UAM).
prEtransplant

Compatibility tEst algorithm
At present, the consensus [5] is that besides a cell-based assay, SPI must be used for the detection of pretransplantation HLA antibodies in solid organ 
